Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
14 mrt 2006 - 08:26
Statutaire naam
Crucell N.V.
Titel
Crucell and DSM Biologics Announce PER.C6® Licensing Agreement with UCB
Bericht
Dutch biotechnology company Crucell N.V. (Euronext and NASDAQ: CRXL; Swiss Exchange: SW CRX) and allied contract manufacturer DSM Biologics announced today that they have signed a PER.C6® research license agreement with global biopharmaceutical leader UCB S.A. (Euronext: UCB). This agreement allows UCB to evaluate the PER.C6® cell line for research and manufacturing of monoclonal antibodies. Financial details were not disclosed.
Datum laatste update: 23 maart 2025